Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
- 31 March 2005
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 23 (19), 2530-2539
- https://doi.org/10.1016/j.vaccine.2004.08.049
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Biochemical and Immunological Characterization of Bacterially Expressed and RefoldedPlasmodium falciparum42-Kilodalton C-Terminal Merozoite Surface Protein 1Infection and Immunity, 2003
- Rate of Degradation of α-Tocopherol, Squalene, Phenolics, and Polyunsaturated Fatty Acids in Olive Oil during Different Storage ConditionsJournal of Agricultural and Food Chemistry, 2002
- A Recombinant Blood‐Stage Malaria Vaccine ReducesPlasmodium falciparumDensity and Exerts Selective Pressure on Parasite Populations in a Phase 1–2b Trial in Papua New GuineaThe Journal of Infectious Diseases, 2002
- A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteersVaccine, 2001
- Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect MosquitoesInfection and Immunity, 2000
- Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteersVaccine, 2000
- Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoidVaccine, 1999
- Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720Vaccine, 1997
- The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivityVaccine, 1992
- SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINEThe Lancet, 1987